By 2030, it is anticipated that the Indonesia infectious disease therapeutics market will reach a value of $1011 Mn from $719.22 Mn in 2022, growing at a CAGR of 4.4% during 2022-2030. Infectious Disease Therapeutics in Indonesia is dominated by a few domestic pharmaceutical companies such as Pharos Indonesia, Bio Farma and Kalbe Farma. The Infectious Disease Therapeutics market in Indonesia is segmented into different therapeutic areas and different diseases type. The major factors affecting the Indonesia infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Indonesia.
By 2030, it is anticipated that the Indonesia infectious disease therapeutics market will reach a value of $1011 Mn from $719.22 Mn in 2022, growing at a CAGR of 4.4% during 2022-2030.
Indonesia is a lower middle-income, developing country located in Southeastern Asia between the Indonesian Ocean and the Pacific Ocean. Indonesia, according to the World Factbook, is very vulnerable to infectious diseases. Bacterial diarrhoea, hepatitis A and E, and typhoid fever are all examples of food or waterborne illnesses. Dengue fever and malaria are two vector-borne diseases that are quite common in Indonesia. Proper sanitation is critical in limiting the spread of infectious diseases, which are more severe in poor communities with limited access to healthcare. Diarrhoea is the leading cause of child mortality in Indonesia. Typhoid is another major threat to Indonesian health. Both diarrhoea and typhoid are exacerbated by poor sanitation, poor hygiene, and a scarcity of clean water.
In Indonesia, there has been an increase in investment in the research and development of new medicines for infectious diseases. This includes both public and private investments, with the government providing incentives for local manufacturers to develop new drugs and vaccines. Indonesia's government spends 3.4% of its GDP on healthcare.
Market Growth Drivers Analysis
The Indonesian government has been adopting a number of steps to alleviate the country's growing burden of infectious diseases. For example, the government has initiated a programme to eliminate tuberculosis by 2050, including free diagnosis and treatment. Low labour costs and a demographic dividend give a competitive advantage while doing business in Indonesia. The Business Process Outsourcing (BPO) industry in Indonesia is thriving. These aspects could boost Indonesia infectious disease therapeutics market.
Market Restraints
The government's healthcare investment in Indonesia is relatively low, which can limit the availability and affordability of infectious disease medicines for many patients. In Indonesia, medication adherence might be low, limiting the efficiency of infectious illness therapies and contributing to the spread of infectious diseases. Indonesia is vulnerable to swings in Chinese demand, as well as ongoing corruption and a lack of openness. These factors may deter new entrants into the Indonesia infectious disease therapeutics market.
Key Players
July 2022: Bio Farma, the parent company of Indonesia's pharmaceutical state-owned enterprises (SOEs), today introduced a new digital health programme called "Preventive Care Medwell," in support of the government's "Healthy Indonesia" blueprint and vision. The organisations have created "ConnectedLife with Fitbit," a personalised wellness and population health virtual platform, the first of its kind in Indonesia, to enable Indonesians to take decisive measures toward healthy living and chronic disease prevention.
December 2022: PT Kalbe Farma Tbk (Kalbe) has signed a memorandum of understanding (MoU) with Monash University of Indonesia as part of Kalbe's long-term commitment as an Indonesian pharmaceutical firm to strengthening the competence of Kalbe employees in the global marketplace.
The National Agency of Drug and Food Control (BPOM) and the Ministry of Health are largely in charge of the regulation and reimbursement of infectious disease medicines in Indonesia (MOH). In Indonesia, the Health Social Security Agency (BPJS) and the National Health Insurance (JKN) programme are in charge of the reimbursement procedure for infectious illness medicines.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Indonesia infectious disease therapeutics market will reach a value of $1011 Mn from $719.22 Mn in 2022, growing at a CAGR of 4.4% during 2022-2030.
The National Agency of Drug and Food Control (BPOM) and the Ministry of Health are largely in charge of the regulation and reimbursement of infectious disease medicines in Indonesia (MOH). In Indonesia, the Health Social Security Agency (BPJS) and the National Health Insurance (JKN) programme are in charge of the reimbursement.
Infectious Disease Therapeutics in Indonesia is dominated by a few domestic pharmaceutical companies such as Pharos Indonesia, Bio Farma and Kalbe Farma.